A recent Office of Inspector General (OIG) report on Medicare’s utilization of one of the highest paid molecular pathology genetic tests caught my attention. You can read a summary of […]

So far in our Evaluation and Management Services blog series, we have gone over changes related to medical decision making (MDM), specifically changes to the first, second, and third elements. […]

I’ve been talking about this for years. I still see folks who don’t think compliance with medical necessity polices is critical. Believe me, I understand human nature; noncompliance can be […]

In late December 2017, I was asked by a colleague for my opinion on a customer’s inquiry about modifier 52 and its use in mammograms. CPT® modifier 52 represents a […]